Express Pharma

Relmada’s depression drug fails to meet late-stage study goal

Relmada will continue to study REL-1017, its lead treatment, as an adjuntive or in combination with other depression drugs

0 150

Relmada Therapeutics said yesterday its therapy to treat major depressive disorder did not meet the main goal of a late-stage study.

The drug, REL-1017, did not show statistically significant improvement in symptoms of depression when compared to a placebo.

Relmada will continue to study REL-1017, its lead treatment, as an adjuntive or in combination with other depression drugs.

Major depressive disorder is a chronic condition that makes patients feel low, experience guilt and worthlessness. In extreme cases, it may lead to suicide.

Edits by EP News Bureau

- Advertisement -